Pituitary adenylate cyclase-activating polypeptide (PACAP) is a pleiotropic 29 neuropeptide hormone functioning in the central nervous system and peripheral tissues. 30
-5 -difference is observed in TM7, which is kinked at the highly conserved G393 7.50 in the 114 other class B GPCRs. PAC1R has an additional glycine G389 7.46 near G393 7.50 , and thus 115 TM7 unwinds and bends around G389 7.46 in the current structure ( Fig. 1d ). However, 116 the G389 7.46 A mutation, which would facilitate the α-helical formation of the unwound 117 TM7, did not alter the Gs-coupling activity ( Supplementary Fig. 1a , b, and Table 1) . 118
This result suggests that this unwinding in TM7 is not related to the PAC1R function. 119 120
Interaction between PACAP and PAC1R-TMD 121
We observed an unambiguous density extending from the TMD, which allowed 122 us to assign the secondary structure and side-chain orientations of PACAP ( Fig. 2a) . The 123 N-terminus of the peptide ligand PACAP is directed toward the TMD core, as in the 124 other class B GPCR structures. The H1 to L27 residues of PACAP form a continuous 125 α-helix and protrude from the transmembrane binding pocket. By contrast, the residues 126 after G28 are disordered, consistent with the fact that the C-terminal truncated variant 127 PACAP1-27 has the same affinity as PACAP. Notably, the N-terminal four residues (H1 128 to G4) form a continuous α-helix, together with the I5 to L27 residues, while these 129 residues were disordered in the previous nuclear magnetic resonance (NMR) structure 130 of PACAP1-27 bound to detergent micelles 17 . These residues are recognized by 13 131 residues of the receptor, and G4 of PACAP closely contacts the W306 5.36 side chain of 132 the receptor (Fig. 2b, c) . These interactions stabilize the α-helical structure at the 133 N-terminus of PACAP, which is essential for receptor activation. 134
The N-terminal 17 residues of PACAP create an extensive interaction network 135 with TM 1-3, 5, 7, and ECL2 of the receptor (Fig. 2b, c) . The details are summarized in 136 Supplementary Table 1 . Notably, PACAP forms numerous interactions with the 137 extracellular portion of TM1, involving the aromatic residues of PACAP (F6, Y10, and 138 Y13), PAC1R (Y150 1.36 , Y157 1.43 , and Y161 1.47 ), and four hydrogen-bonding 139 interactions (D3-Y161 1.47 , S9-Y150 1.36 , Y10-K154 1.40 , and Y13-D147 1.33 ) ( Fig. 2b-e ). 140
These close interactions with TM1 are not observed in the other class B GPCR 141 structures ( Supplementary Fig. 4a-d) , and are a unique feature of the PACAP-PAC1R 142 structure. 143 -6 -PACAP can activate three types of PACAP receptors, PAC1R, VPAC1R, and 144 VPAC2R with similar affinities 4 . To investigate the similarity in their ligand recognition, 145
we mapped the conserved residues on the current structure ( Fig. 2d , e, and 146 Supplementary Fig. 5 ). Notably, the residues involved in the ligand recognition are 147 highly conserved in TM1, suggesting that TM1 plays a critical role in the PACAP 148 recognition by the receptors. 149 150
Structural insight into G-protein activation 151
In the class B GPCRs, ligand binding induces the rearrangement of the central 152 polar interaction network, followed by the unwinding of TM6 at the highly conserved 153 P 6.47 -X-X-G 6.50 motif and the opening of the intracellular cavity of the receptor for 154 G-protein coupling 12, 13, 14 . In the central region of PAC1R, we observed a similar polar 155 interaction network and the unwinding of TM6 (Fig. 3a, b ). The polar interaction 156 network comprises D3 of PACAP and Y161 1.47 , R199 2.60 , N240 3.43 , Y241 3.44 , P360 6.47 , 157 G363 6.50 , H365 6.52 , Y366 6.53 , and Q392 7.49 of the receptor. Notably, D3 forms a hydrogen 158 bond with Y161 1.47 and an electrostatic interaction with R260 2.60 . R260 2.60 in turn forms 159 a hydrogen bond with Y241 3.44 . Y366 6.53 , in the extracellular portion of TM6, is directed 160 toward the receptor core and participates in this network. Overall, this polar interaction 161 network extends from D3 to the carbonyl oxygens of P360 6.47 and G363 6.50 in TM6. A 162 previous SAR study showed that the substitution of D3 with alanine reduces both the 163 Emax value to 70% and the affinity for the receptor 4 . Therefore, PACAP binding directly 164 induces the rearrangement of the polar interaction network in the central region and 165 plays a key role in receptor activation, by unwinding TM6. 166 TM6 is kinked at P360 6.47 and G363 6.50 in the P 6.50 -X-X-G 6.53 motif, as in the 167 other Gs-complexed class B GPCR structures. Notably, the kink at G363 6.50 is sharp (~ 168 90°), whereas that at P360 6.47 is to a less extent ( Fig. 3b ). Previous mutational studies of 169 the calcitonin receptor family members suggested the functional importance of P 6.47 in 170 receptor activation 18, 19 . However, the P360 6.47 A mutation to PAC1R did not alter the 171 Gs-coupling activity ( Fig. 3c and Table 1 ). By contrast, the G363 6.50 A mutation 172 completely abolished the activity, suggesting that G363 6.50 , rather than P360 6.47 , is 173 -7 -responsible for the TM6 unwinding upon receptor activation, consistent with the 174 structural observations. 175
The intracellular cavity of the receptor closely contacts the α5-helix of Gs, 176 which is the primary determinant for the G-protein coupling (Fig. 3a, d) . Specifically, 177 S354 6.41 in TM6 directly hydrogen bonds with the carbonyl oxygen of L393. K334 5.64 in 178 TM5 forms a salt bridge with D381, and the carbonyl oxygens of L255 and V256 in 179 ICL2 hydrogen bond with Q384 and K380, respectively. These interactions are also 180 observed in other Gs-complexed class B GPCR structures 13,16 ( Fig. 3e, f ), suggesting 181 that they are conserved structural features of the Gs-coupling in class B GPCRs. 182 183
Diverged functional role of ECDs in class B GPCRs 184
The class B GPCRs have an ECD (about 120 amino acids) at the N-terminus, 185 which is commonly important for the initial, high-affinity binding to peptide hormones. 186
Although the ECD is less well resolved in our EM map, probably due to its flexibility, 187 we could fit the ECD region of the previous PAC1R-ECD crystal structure (PDB code: 188 3N94) 9 onto the map by a rigid body. This model can facilitate discussions about the 189 interactions between PACAP and the ECD (Fig. 4a ). The PAC1R-ECD adopts a 190 three-layer α-β-βα fold, which is conserved in the class B GPCRs. The C-terminal 191 portion of PACAP (Q16, V19, Y22, L23, and L27) interacts with the loops connecting 192 β1-β2 and β3-β4, and the N-terminal ends of α-helix 1 and α-helix 2 in the PAC1R- ECD, 193 as in other class B GPCRs ( Supplementary Fig. 4e -g). Furthermore, the PAC1R-ECD 194 has an additional α-helix, α-helix 3, in the loop connecting β3-β4, which closely 195 contacts PACAP. A previous study showed that the N-terminal splice variant 196 PAC1R-short 20 , which lacks residues 89-109 between the α-helix 3 and β4, exhibits 197 increased affinity for PACAP. While residues 89-110 are not modeled in our EM map, 198 we suggest that the truncation affects the conformation of the α-helix 3 and enhances 199 the interaction with PACAP. 200
The ECD in class B GPCRs also plays a key role in receptor activation. Previous 201 functional analyses demonstrated that the ECD-truncated GLP1R does not respond to 202 GLP1 21 . In the GLP1R structure, the ECD covers the top of the C-terminal portion of 203 -8 -GLP1, to facilitate the interactions between the N-terminal portion of GLP1 and TMD 204 ( Fig. 4b ). However, the PAC1R-ECD tilts by ~40° as compared with the GLP1R-ECD 205 ( Fig. 4c, d) , and thus it only interacts with the side of the C-terminal portion of PACAP, 206
suggesting the different role of the PAC1R-ECD. 207
To investigate the function of the PAC1R-ECD, we truncated the C-terminal 208 portion of PACAP (residues 18-38) that interacts with the ECD (Fig. 5a ). The truncated 209 peptide PACAP1-17 activated the receptor at the same level, as compared with PACAP in 210 the NanoBiT-G-protein dissociation assay, while its EC50 was significantly increased by 211 about 6000-fold ( Fig. 5b and Table 3 ), suggesting that PACAP1-17 is capable of 212 functioning as a full agonist for PAC1R. Moreover, PACAP and PACAP1-17 also 213 activated the ECD-truncated PAC1R to mostly the same level ( Fig. 5c , Table 3 , and 214 Supplementary Fig. 1b ). These results indicate that the PAC1R-ECD functions merely 215 as an affinity trap to bind and precisely localize the peptide hormone to the receptor, 216
whereas the interaction between PACAP and the PAC1R-TMD is necessary and 217 sufficient for receptor activation. This observation is consistent with the previous study, 218 which showed that the PAC1R-TMD covalently linked to the PACAP1-12 at the 219 N-terminus constitutively activates the G-protein 21 . By contrast, GLP17-23, which lacks 220 the C-terminal portion of GLP ( Fig. 5d ), completely lost the agonist activity for GLP1R 221 ( Fig. 5e and Table 3 ). Furthermore, the ECD-truncated GLP1R was poorly expressed 222 and lacked receptor activity ( Fig. 5f and Supplementary Fig. 1c ). These results 223 confirmed that the GLP1R-ECD plays an indispensable role in receptor activation. 224
While the ECDs are commonly essential for ligand recognition in the class B GPCRs, 225 their contributions to receptor activation diverge among the receptors. 226
227

Discussion
228
We determined the PAC1R structure in complex with PACAP and the Gs-protein, 229 which revealed a unique interaction between PACAP and the PAC1R-TMD, involving 230 the aromatic residues in PACAP and TM1. Structural observations and functional 231 analyses indicated that the interaction between PACAP and the TMD is necessary and 232 sufficient for receptor activation, while the ECD is only required for the high-affinity 233 -9 -binding. Our structural information will help the design of novel peptide-mimetic 234 agonists for PAC1R, to treat dry eye syndrome and mental disorders. The N-terminal signal sequence in human PAC1R (Genbank ID: AK290046) 345 was replaced with the haemagglutinin signal peptide. The C-terminus was truncated 346 after S417. The modified receptor was subcloned into a modified pFastBac vector 25 , 347 with the resulting construct encoding a TEV cleavage site followed by a GFP-His 10 tag 348 at the C-terminus. The recombinant baculovirus was prepared using the Bac-to-Bac 349 The movie frames were aligned in 5 × 5 patches, dose weighted, and binned by 2 450 in MotionCor2 27 . Defocus parameters were estimated by CTFFIND 4.1 28 . First, 451 template-based auto-picking was performed with the two-dimensional class averages of 452 a few hundred manually picked particles as templates. A total of 980,964 particles were 453 extracted in 3.24 Å pixel −1 . These particles were subjected to three rounds of 454 two-dimensional classification in RELION 3.0. The initial model was generated in 455 RELION-3.0 28 . Subsequently, 980,964 particles were further classified in 3D without 456 symmetry. Two stable classes showed detailed features for all subunits. One contained a 457 single complex (monomer class). The other contained two complexes in an inverted 458 -19 -molecular packing with C2 symmetry (dimer class). The particles of the monomer and 459 dimer classes were 282,622 and 132,808 particles, respectively, were then re-extracted 460 with the original pixel size of 1.35 Å pixel, and subsequently subjected to 3D refinement. 461
The resulting 3D models and particle sets were subjected to per-particle defocus 462 refinement, Bayesian polishing, and 3D refinement. The final 3D refinement and 463 postprocessing yielded maps of the monomer and dimer classes with global resolutions 464 of 4.5 Å and 4.0 Å, respectively. The comparison of the density maps of the two classes 465 suggested almost identical conformation, and therefore, we built an atomic model onto 466 the higher resolution map of the dimer class. All density maps were sharpened by 467 applying the temperature-factor, which was estimated using the post-processing in 468 RELION-3.1. The local resolution was estimated by RELION-3.1. The processing 469 strategy is described in Supplementary figure 2 . 470 471
Model building and refinement 472
The initial template for the PAC1R transmembrane regions, PACAP, G-protein, 473
and Nb35 was derived from the structure of human GLP1R in complex with a 474 dominant-negative Gαs (PDB code: 6B3J), followed by extensive remodeling using 475 COOT 29 . Owing to the discontinuous and/or variable density in the ECD region, we 476 assigned the high-resolution X-ray crystal structure of the PAC1R (PDB code: 3N94) 9 477 by a rigid body fit, and the model was rebuilt using Rosetta 30 against the density, 478 manually readjusted using COOT, and refined using phenix.real_space_refine 31 . 479 Validation was performed in MolProbity 32 . The potential overfitting of the refined 480 models was tested by using a cross-validation method, as described previously. Briefly, 481 the final models were 'shaken' by introducing random shifts to the atomic coordinates 482 with an rms of 0.5 Å, and were refined against the first half map. These shaken refined 483 models were used to calculate the FSC against the same first half maps (FSChalf1 or 484 work), and the second half maps (FSChalf2 or free) that were not used for the refinement, 485 using phenix.mtriage. The small differences between the FSChalf1 and FSChalf2 curves 486 indicated no severe overfitting of the models. The curves representing model vs. full 487 -20 -map were calculated, based on the final model and the full, filtered and sharpened map. 488
The statistics of the 3D reconstruction and model refinement are summarized in Table 2 . 489
All molecular graphics figures were prepared with CueMol (http://www.cuemol.org) 490 and UCSF Chimera 33 . 491 492 NanoBit G-protein dissociation assay 493 PAC1R-and GLP1R-induced Gs activation was measured by a 494
NanoBiT-G-protein dissociation assay 10 , in which the interaction between a Gα subunit 495 and a Gβγ subunit was monitored by a NanoBiT system (Promega). Specifically, a 496
NanoBiT-Gs protein consisting of a large fragment (LgBiT)-containing Gαs subunit and 497 a small fragment (SmBiT)-fused Gγ2 subunit, along with the untagged Gβ1 subunit, was 498 expressed with a test GPCR, and the ligand-induced luminescent signal change was 499 measured. We used the N-terminal FLAG (DYKDDDK) tagged constructs of the human 500 PAC1R, PAC1RΔECD (148-468), GLP1R, and GLP1RΔECD (140-463). HEK293 cells 501 deficient for Gq/11 34 were seeded in a 6-well culture plate at a concentration of 2 x 10 5 502 cells ml -1 (2 ml per well in DMEM (Nissui Pharmaceutical) supplemented with 10% 503 fetal bovine serum (Gibco), glutamine, penicillin, and streptomycin), one day before 504 transfection. The transfection solution was prepared by combining 4 µl (per well 505 hereafter) of polyethylenimine solution (Polysciences, 1 mg ml -1 ) and a plasmid mixture 506 consisting of 100 ng LgBiT-containing Gαs subunit, 500 ng Gβ1, 500 ng SmBiT-fused 507 Gγ2, and 200 ng test GPCR (or an empty plasmid) in 200 µl of Opti-MEM 508 (ThermoFisher Scientific). To prepare a larger volume of transfected cells, 10-cm 509 culture dishes (10 ml culture volume) were used with 5-fold scaling of the 6-well plate 510 contents. After an incubation for one day, the transfected cells were harvested with 0.5 511 mM EDTA-containing Dulbecco's PBS, centrifuged, and suspended in 2 ml of HBSS 512 containing 0.01% bovine serum albumin (BSA fatty acid-free grade, SERVA) and 5 513 mM HEPES (pH 7.4) (assay buffer). The cell suspension was dispensed in a white 514 96-well plate at a volume of 80 µl per well, and loaded with 20 µl of 50 µM 515 coelenterazine (Carbosynth), diluted in the assay buffer. After 1 h incubation at room 516 -21 -temperature, the titrated antagonist (Atropine, NMS, or Tiotropium), diluted in the assay 517 buffer at 10X of the final concentration, was added at a volume of 10 µl per well. After 518 2 h incubation, the plate was measured for baseline luminescence (Spectramax L, 519
Molecular Devices) and 20 µl portions of 6X test compound, diluted in the assay buffer, 520 were manually added. After an incubation for 3-5 minutes at room temperature, the 521 plate was read for the second measurement. The second luminescence counts were 522 normalized to the initial counts, and the fold-changes in the signals over the vehicle 523 treatment were plotted for the G-protein dissociation response. Using the Prism 8 524 software (GraphPad Prism), the G-protein dissociation signals were fitted to a 525 four-parameter sigmoidal concentration-response curve, from which the pEC50 values 526 (negative logarithmic values of EC50 values) were used to calculate the mean and SEM. 527
The pEC50 values for PACAP-17 were calculated by restraining the "Shared values for 528 all datasets" for the "Top" and "Bottom" parameters, using both PACAP-17 and 529 PACAP-38. 530
Flow cytometry analysis 531
Gq/11-deficient HEK293 cells 34 were seeded in a 12-well culture plate at a 532 concentration of 2 x 10 5 cells ml -1 (1 ml per well), one day before transfection. The 533 transfection solution was prepared by combining 2 µl of the polyethylenimine solution 534
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